文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-Fluciclovine靶向前列腺穿刺参数与复发性前列腺癌真阳性相关

18F-Fluciclovine Parameters on Targeted Prostate Biopsy Associated with True Positivity in Recurrent Prostate Cancer.
PubMed 文献 · J Nucl Med · 2019-04-06

本研究评估了非前列腺切除术后生化复发患者中,18F-Fluciclovine PET/CT摄取参数与靶向前列腺穿刺真阳性(恶性)的相关性。21例患者共50个病灶,17个(34.0%)为恶性。真阳性病灶的SUVmax、骨髓TBR和血池TBR在早期显像显著更高(P<0.01),延迟显像除血池TBR外仍显著。局灶性摄取和主观最高怀疑等级与真阳性相关。骨髓TBR早期最佳截断值1.9(AUC 0.82),延迟1.8(AUC 0.85)。

要点

  • 18F-Fluciclovine靶向穿刺真阳性与局灶性摄取、骨髓/血池TBR及主观最高怀疑等级相关。
  • 骨髓TBR早期截断值1.9、延迟1.8可优化鉴别,延迟显像减少假阳性。
  • 前列腺内阳性预测值仅34.0%,应用这些参数可能提高真阳性率。

核心结论

  • 非前列腺切除术后患者中,18F-Fluciclovine靶向穿刺真阳性与局灶性摄取、骨髓和血池TBR及主观最高怀疑等级相关。
  • 骨髓TBR早期1.9、延迟1.8具有最佳鉴别能力,应用这些参数可能提高治疗后前列腺的真阳性率。

研究设计与样本

  • 前瞻性研究纳入21例非前列腺切除术后生化复发患者(PSA 7.4±6.8 ng/mL),行双时间点18F-Fluciclovine(364.1±37.7 MBq)PET/CT。
  • PET/CT图像与前列腺穿刺计划超声配准,对18F-Fluciclovine定义的目标行经直肠穿刺,并进行组织学分析。
  • 比较真阳性(恶性)与假阳性(良性)病灶的SUVmax、TBR、摄取模式和主观怀疑等级,采用单因素分析和ROC曲线确定TBR截断值,P<0.05为显著。

主要发现

  • 21例患者共识别50个病灶,其中17个(34.0%)为恶性,分布于10例患者。
  • 早期显像真阳性病灶SUVmax(6.62±1.70 vs. 4.92±1.27)、骨髓TBR(2.57±0.81 vs. 1.69±0.51)和血池TBR(4.10±1.17 vs. 2.99±1.01)均显著高于假阳性(P<0.01)。
  • 延迟显像上述差异除血池TBR外仍显著。
  • 局灶性摄取(OR 12.07,95%CI 2.98-48.80,P<0.01)和主观最高怀疑等级(OR 10.91,95%CI 1.19-99.69,P=0.03)与真阳性相关。
  • 骨髓TBR最佳截断值早期1.9(AUC 0.82)、延迟1.8(AUC 0.85);按此截断值,两个时间点均识别15/17恶性病灶,延迟显像假阳性病灶(5/33)少于早期(11/33)。

关键数值与推荐

  • 骨髓TBR早期最佳截断值1.9(AUC 0.82),延迟最佳截断值1.8(AUC 0.85)。
  • 局灶性摄取OR 12.07(95%CI 2.98-48.80,P<0.01),主观最高怀疑等级OR 10.91(95%CI 1.19-99.69,P=0.03)。

临床怎么用

  • 对非前列腺切除术后生化复发患者行18F-Fluciclovine PET/CT时,可结合局灶性摄取、骨髓TBR和主观怀疑等级解读。
  • 采用骨髓TBR早期1.9、延迟1.8的截断值可能提高靶向穿刺真阳性率,延迟显像有助于减少假阳性。

局限性

  • 样本量较小(21例患者,50个病灶),前列腺内阳性预测值较低(34.0%)。
  • 单中心研究,需更大样本验证截断值和解读标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluated 18F-fluciclovine uptake parameters that correlate with true positivity for local recurrence in non-prostatectomy-treated patients. Methods: Twenty-one patients (prostate-specific antigen level, 7.4 ± 6.8 ng/mL) with biochemical recurrence after nonprostatectomy local therapy (radiotherapy and cryotherapy) underwent dual-time-point 18F-fluciclovine (364.1 ± 37.7 MBq) PET/CT from pelvis to diaphragm. Prostatic uptake over background was delineated and coregistered to a prostate-biopsy-planning ultrasound. Transrectal biopsies of 18F-fluciclovine-defined targets were completed using a 3-dimensional visualization and navigation platform. Histologic analyses of lesions were completed. Lesion characteristics including SUVmax, target-to-background ratio (TBR), uptake pattern, and subjective reader's suspicion level were compared between true-positive (malignant) and false-positive (benign) lesions. Univariate analysis was used to determine the association between PET and histologic findings. Receiver-operating-characteristic curves were plotted to determine discriminatory cutoffs for TBR. Statistical significance was set at a P value of less than 0.05. Results: Fifty lesions were identified in 21 patients on PET. Seventeen of 50 (34.0%) targeted lesions in 10 of 21 patients were positive for malignancy. True-positive lesions had a significantly higher SUVmax (6.62 ± 1.70 vs. 4.92 ± 1.27), marrow TBR (2.57 ± 0.81 vs. 1.69 ± 0.51), and blood-pool TBR (4.10 ± 1.17 vs. 2.99 ± 1.01) than false-positive lesions at the early time point (P < 0.01) and remained significant at the delayed time point, except for blood-pool TBR. Focal uptake (odds ratio, 12.07; 95% confidence interval, 2.98-48.80; P < 0.01) and subjective highest suspicion level (odds ratio, 10.91; 95% confidence interval, 1.19-99.69; P = 0.03) correlated with true positivity. Using the receiver-operating-characteristic curve, optimal cutoffs for marrow TBR were 1.9 (area under the curve, 0.82) and 1.8 (area under the curve, 0.85) at early and delayed imaging, respectively. With these cutoffs, 15 of 17 malignant lesions were identified at both time points; however, fewer false-positive lesions were detected at the delayed time point (5/33) than at the early time point (11/33). Conclusion: True positivity of 18F-fluciclovine-targeted prostate biopsy in non-prostatectomy-treated patients correlates with focal uptake, TBR (blood pool and marrow), and subjective highest suspicion level. A marrow TBR of 1.9 at the early time point and 1.8 at the delayed time point had optimal discriminating capabilities. Despite the relatively low intraprostate positive predictive value (34.0%) with 18F-fluciclovine, application of these parameters to interpretative criteria may improve true positivity in the treated prostate.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Abiodun-Ojo OA, Akintayo AA, Akin-Akintayo OO, et al. 18F-Fluciclovine Parameters on Targeted Prostate Biopsy Associated with True Positivity in Recurrent Prostate Cancer. J Nucl Med. 2019. PMID: 30954940. doi:10.2967/jnumed.119.227033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。